Evidence record · ER-BPC157-GUT-003
Does BPC-157 repair the gut lining in people?
BPC-157 promotes gut or mucosal repair in people
BPC-157 does not have dependable human evidence for repairing the gut lining or treating gastrointestinal disease. Animal and laboratory studies may support biological plausibility, but they do not show symptom relief, endoscopic healing, fewer relapses or safer outcomes in people using a characterised BPC-157 product.
Claim boundary
What this verdict covers
“Gut repair” is separated into defined human outcomes such as symptom change, endoscopic healing, relapse or hospitalisation in a diagnosed condition. A general wellness claim cannot be inferred from an animal model.
- Compound
- BPC-157
- Population
- People with gastrointestinal symptoms or disease
- Outcome
- Symptoms, healing or disease control
- Record ID
- ER-BPC157-GUT-003
Evidence synthesis
What the research can support
The BPC-157 literature is dominated by preclinical models. The recent systematic review did not identify a dependable controlled human programme for gastrointestinal outcomes. Differences between induced animal injury and human disease make direct translation especially uncertain.
Why the confidence is very low
No suitable human efficacy trial, pharmacokinetic programme or adequate safety database was identified. The claim also fails to name a condition, making it broader than any single study could support.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-BPC157-GUT-003 addresses one bounded question: Does BPC-157 repair the gut lining in people?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Preclinical only, the verdict is Insufficient and confidence is Very low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| 2025 systematic review of BPC-157 | The review maps a predominantly preclinical BPC-157 evidence base. | It does not establish mucosal healing in people. | 10 August 2026 |
| FDA BPC-157 compounding review | FDA assessed the available evidence and unresolved safety questions. | It is not a human gut-treatment trial. | 10 August 2026 |
| FDA bulk-substance safety page | FDA notes limited human safety information and peptide-quality concerns. | It does not test a specific consumer product. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on BPC-157 for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
The BPC-157 literature is dominated by preclinical models. The recent systematic review did not identify a dependable controlled human programme for gastrointestinal outcomes. Differences between induced animal injury and human disease make direct translation especially uncertain. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is BPC-157 authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
BPC-157 is named on the 2026 WADA Prohibited List under non-approved substances and is prohibited at all times. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion. Read the cited source and stated scope together before relying on it.
What could change this verdict?
A registered human trial in a named gastrointestinal condition, using objective disease measures, patient-reported outcomes, adequate follow-up and a fully characterised product. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation